The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Additionally, by the fourth week of the study, 22.5% of participants taking 84 milligram (mg) doses of Spravato achieved MDD remission with an MADRS total score of less than or equal to 12 ...
Medpage Today on MSN16d
FDA Expands Approval of Esketamine for DepressionThe FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...
Officially, Janssen (the manufacturer of Spravato) recommends dosages up to 84 mg (i.e., six sprays or three spray bottles); however, unofficially, I've worked with patients taking Spravato who ...
WEST HARTFORD, CT (WFSB) – A man was killed in a two-vehicle crash on Interstate 84 in West Hartford early Monday morning. State police identified the man as 30-year-old Tamek Nelson Skinner of ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
HealthDay on MSN14d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback